Jeffrey S. Farrow - 05 Mar 2026 Form 4 Insider Report for Tarsus Pharmaceuticals, Inc. (TARS)

Reporting relationship: Chief Financial Officer and Chief Strategy Officer
Issuer ticker: TARS
Reported as of: 05 Mar 2026
Net transaction value: $0
SEC form: 4
Accepted by SEC: 09 Mar 2026, 16:06:51 UTC
Prior SEC filing: 18 Jun 2025
Next SEC filing: 17 Mar 2026
Source filing: View source filing
Reporting owner signature: /s/ Jeffrey Farrow

Key filing fact

Jeffrey S. Farrow filed Form 4 for Tarsus Pharmaceuticals, Inc. (TARS) on 09 Mar 2026.

Key facts

This page summarizes Jeffrey S. Farrow's Form 4 filing for Tarsus Pharmaceuticals, Inc. (TARS).
2 reported transactions and 2 derivative rows are listed below.
Accepted by SEC: 09 Mar 2026, 16:06.

Change

Previous filing in this sequence was filed on 18 Jun 2025.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0001405253 Primary reporting owner

Farrow Jeffrey S

Relationship: Chief Financial Officer and Chief Strategy Officer
Address: C/O TARSUS PHARMACEUTICALS, INC., 15440 LAGUNA CANYON ROAD, SUITE 160, IRVINE
Signature: /s/ Jeffrey Farrow
Signature date: 09 Mar 2026

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

TARS transaction Derivative

Stock Option (right to buy)

Award

Transaction value
Shares: +30,724
Change %
Price: $0.000000^*
Shares after: 30,724
Date: 05 Mar 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 30,724
Exercise price: $74.90
Footnotes: F1

TARS transaction Derivative

Restricted Stock Units

Award

Transaction value
Shares: +19,306
Change %
Price: $0.000000^*
Shares after: 19,306
Date: 05 Mar 2026
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 19,306
Exercise price
Footnotes: F2, F3

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 3 footnotes

Footnote F1

25% of the option shares shall vest on March 5, 2027, and 1/48th of the option shares shall vest each month thereafter for a period of 3 years, subject to the Reporting Person's continuous service.

Footnote F2

Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.

Footnote F3

The RSUs will vest in four equal annual installments on March 15th of each of 2027, 2028, 2029, and 2030, subject to the Reporting Person's continuous service.

SEC remarks

Chief Financial Officer and Chief Strategy Officer